Study guide

10.1 Pharmacokinetics, ADME & Receptor Dynamics

APMLE Part I Basic Sciences Podiatry

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Lower Extremity Osteology

1.1 APMLE Part I Exam Structure, Policies & Scoring 1.2 Foot Osteology: Tarsals, Metatarsals, Phalanges & Sesamoids 1.3 Leg & Ankle Osteology: Tibia, Fibula & The Ankle Mortise 1.4 Pelvis, Femur & Patella Osteology: Landmarks & Biomechanics

2 Chapter 2: Lower Extremity Arthrology & Ligaments

2.1 Foot Articulations: Subtalar, Midtarsal, Lisfranc & Digital Joints 2.2 Talocrural (Ankle) & Knee Joints: Ligaments & Kinematics 2.3 Hip Joint & Pelvic Articulations: Capsular Structures & Dynamics

3 Chapter 3: Lower Extremity Myology & Compartments

3.1 Anterior & Lateral Compartments of the Leg 3.2 Superficial & Deep Posterior Compartments of the Leg 3.3 Plantar Layers & Intrinsic Musculature of the Foot 3.4 Thigh & Gluteal Musculature: Attachments & Innervations

4 Chapter 4: Lower Extremity Neurovascular & Topographical Anatomy

4.1 Lumbar & Sacral Plexuses, Peripheral Nerves & Dermatomes 4.2 Arterial Network, Venous Drainage & Lymphatics 4.3 Tarsal Tunnel, Femoral Triangle & Topographical Spaces

5 Chapter 5: Microbiology: Bacteriology, Zoonoses & Laboratory Methods

5.1 Gram-Positive Cocci & Bacilli in Podiatric Infections 5.2 Gram-Negative Bacilli & Opportunistic Pathogens 5.3 Anaerobic Pathogens & Diabetic Foot Infections 5.4 Bacterial Structure, Virulence Factors & Sterilization 5.5 Mycobacteria, Spirochetes, Mycoplasma & Zoonotic Infections 5.6 Antimicrobial Resistance, Susceptibility Testing, Specimen Handling & Vaccines

6 Chapter 6: Mycology, Virology, Parasitology & Clinical Immunology

6.1 Mycology: Dermatophytes, Onychomycosis & Systemic Mycoses 6.2 Clinically Relevant Viruses & Parasitic Infections 6.3 Innate & Adaptive Immunity Mechanisms 6.4 Hypersensitivity Reactions, Immunodeficiencies & Autoimmunity 6.5 Transplant & Tumor Immunology and Immunodiagnostic Methods

7 Chapter 7: General & Cellular Pathology

7.1 Cellular Injury, Adaptations & Cell Death Mechanisms 7.2 Acute vs Chronic Inflammation & Tissue Repair 7.3 Hemodynamic Disorders, Thrombosis, Embolism & Shock 7.4 Neoplasia, Oncogenes, Tumor Suppressors & Cutaneous Tumors

8 Chapter 8: Systemic & Podiatric Pathology

8.1 Atherosclerosis, Peripheral Artery Disease & Diabetic Microangiopathy 8.2 Osteoarthritis, Inflammatory Arthritides & Bone Infections 8.3 Neuropathic Disorders, Charcot Neuroarthropathy & Dermatopathology 8.4 Laboratory Diagnostics, Synovial Fluid & Biopsy Interpretation

9 Chapter 9: Organ-System Pathology

9.1 Anemias, Hemoglobinopathies, Leukemias & Immune Disorders 9.2 Cardiac & Pulmonary Pathology 9.3 Renal, Urogenital & Reproductive Pathology 9.4 Gastrointestinal, Hepatobiliary & Endocrine Pathology

10 Chapter 10: General Pharmacology, Autonomic Drugs & Toxicology

10.1 Pharmacokinetics, ADME & Receptor Dynamics 10.2 Cholinergic Agonists & Muscarinic/Nicotinic Antagonists 10.3 Adrenergic Agonists, Sympatholytics & Clinical Applications 10.4 Cardiovascular Pharmacology in Podiatric Patients 10.5 Drug Interactions, Adverse Effects, Pharmacogenomics & Toxicology

11 Chapter 11: Antimicrobial & Podiatric Therapeutics

11.1 Antibacterial Classes, Mechanisms & Resistances 11.2 Antifungal, Antiviral & Antiparasitic Therapeutics 11.3 NSAIDs, Opioids, Corticosteroids & Anti-Gout Agents 11.4 Local & General Anesthetic Pharmacology

12 Chapter 12: Systemic Pharmacology

12.1 Anticonvulsants, Antidepressants, Psychotropics & Skeletal Muscle Relaxants 12.2 Insulin & Noninsulin Glycemic Agents 12.3 Respiratory & Gastrointestinal Agents 12.4 DMARDs, Biologics, Antineoplastics & Immunosuppressants 12.5 Hormone Therapy, Bisphosphonates, Antihistamines, Growth Factors & Complementary Agents

13 Chapter 13: General Anatomy: Systemic Gross Anatomy & Neuroanatomy

13.1 Cranial Nerves, Head & Neck Anatomy 13.2 Thoracic Wall, Tracheobronchial Tree, Lungs & Mediastinum 13.3 Abdominal Wall, GI Viscera, Pelvis & Retroperitoneum 13.4 Vertebral Column, Spinal Cord & Upper Extremity Overview 13.5 Neuroanatomy: CNS Organization, Somatosensory & Motor Pathways

14 Chapter 14: Histology, Integument, Embryology & Genetics

14.1 Microscopic Anatomy: Epithelia, Connective Tissue, Muscle & Nerve 14.2 Integumentary System: Dermis, Appendages, Nail Unit & Cutaneous Receptors 14.3 Embryogenesis, Limb Morphogenesis & Postnatal Development 14.4 Medical Genetics & Structural Alterations in Aging

15 Chapter 15: Cellular, Neuromuscular & Cardiovascular Physiology

15.1 Membrane Potential, Ion Channels & Transport Mechanisms 15.2 Action Potentials, Synaptic Transmission & Muscle Contraction 15.3 Cardiac Electrophysiology, ECG & Hemodynamics 15.4 Blood Pressure Regulation, Poiseuille Law & Capillary Dynamics

16 Chapter 16: Organ-System Physiology: Respiratory, Renal, Endocrine, GI & Blood

16.1 Pulmonary Mechanics, Gas Exchange & Acid-Base Regulation 16.2 Renal Filtration, Tubular Transport & Fluid/Acid-Base Balance 16.3 Endocrine Regulation, Reproductive Hormones, Calcium & Bone 16.4 Gastrointestinal & Hepatobiliary Physiology 16.5 Hematology: Erythropoiesis, Leukocytes, Platelets & Coagulation 16.6 Exercise Physiology, Thermoregulation & Bone Mechanobiology

17 Chapter 17: Biochemistry: Proteins, Enzymes, Carbohydrates & Signaling

17.1 Amino Acid Chemistry, Protein Structure & Enzyme Kinetics 17.2 Glycolysis, Gluconeogenesis, Glycogen Metabolism & TCA Cycle 17.3 Electron Transport Chain, ATP Synthesis & Metabolic Inborn Errors 17.4 Hormones, Receptors, Second Messengers & Signal Transduction

18 Chapter 18: Biochemistry: Lipids, Molecular Genetics, Blood Chemistry & Nutrition

18.1 Fatty Acid Oxidation, Ketogenesis, Cholesterol & Lipoproteins 18.2 Nucleotide Metabolism, DNA Replication, Transcription, Translation & Repair 18.3 Vitamins, Micronutrients & Inborn Errors of Metabolism 18.4 Blood Chemistry: Heme Metabolism, Hemoglobin & Plasma Proteins 18.5 Nutrition: Energy Balance, Glycemic Index, Fed-Fast Cycle & Free Radicals

10.1 Pharmacokinetics, ADME & Receptor Dynamics

Key Takeaways Explain This Topic AI

Bioavailability (F) quantifies the fraction of an administered drug reaching systemic circulation intact; first-pass hepatic metabolism significantly reduces oral bioavailability relative to intravenous delivery (F = 100%).

The Henderson-Hasselbalch principle dictates that non-ionized (uncharged) drug molecules cross lipid membranes; local anesthetics are weak bases whose efficacy is severely compromised in acidic infected tissue due to ion trapping in the charged conjugate acid form.

Apparent volume of distribution (Vd) reflects drug partitioning between plasma and peripheral tissues; acidic drugs preferentially bind serum albumin, while basic drugs bind alpha-1-acid glycoprotein.

Hepatic metabolism comprises Phase I functionalization (CYP450 oxidation, reduction, hydrolysis) and Phase II conjugation (glucuronidation, acetylation, sulfation); CYP inducers accelerate substrate elimination, whereas CYP inhibitors precipitate drug accumulation and toxicity.

Drug elimination follows first-order kinetics (constant fraction per unit time; constant half-life) or saturable zero-order kinetics (constant amount per unit time; variable half-life e.g., phenytoin, ethanol, high-dose aspirin); steady state is attained after 4 to 5 half-lives.

Last updated: October 2026

10.1 Pharmacokinetics, ADME & Receptor Dynamics

Independent Study Guide Notice: Independent study guide by ExamFinch. This educational resource is developed independently by ExamFinch and is not sponsored, endorsed, or affiliated with the National Board of Podiatric Medical Examiners (NBPME) or Meazure Learning.

Introduction to Pharmacokinetics vs. Pharmacodynamics

Pharmacology is divided into two core conceptual disciplines:

Pharmacokinetics (PK): What the body does to the drug. PK governs the time course of drug concentration in plasma and tissues through the processes of Absorption, Distribution, Metabolism, and Elimination (ADME) .

Pharmacodynamics (PD): What the drug does to the body. PD investigates receptor interactions, biochemical signal transduction cascades, graded and quantal dose-response relationships, and the magnitude of physiologic or toxicologic effects.

Dose Administered → Pharmacokinetics Plasma Concentration → Pharmacodynamics Clinical Effect / Toxicity \text{Dose Administered} \xrightarrow{\textbf{Pharmacokinetics}} \text{Plasma Concentration} \xrightarrow{\textbf{Pharmacodynamics}} \text{Clinical Effect / Toxicity} Dose Administered Pharmacokinetics ​ Plasma Concentration Pharmacodynamics ​ Clinical Effect / Toxicity

  • ADME: Absorption & Bioavailability
  • Absorption Mechanisms

For a pharmacologic agent to exert a systemic effect, it must traverse biological lipid bilayer membranes to enter the vascular compartment. Drug absorption occurs primarily through:

Passive Transcellular Diffusion: Driven by concentration gradients; favored by non-ionized, low-molecular-weight, highly lipophilic molecules.

Facilitated Diffusion & Active Transport: Mediated by membrane solute carrier (SLC) transporters or ATP-binding cassette (ABC) efflux pumps (e.g., P-glycoprotein / MDR1).

Paracellular Transport: Aqueous filtration through intercellular junctions.

Bioavailability ( F F F )

Bioavailability ( F F F ) is defined as the fraction or percentage of an administered drug dose that reaches the systemic circulation in an active, unchanged molecular state:

F = AUC oral AUC IV × 100 % F = \frac{\text{AUC}_{\text{oral}}}{\text{AUC}_{\text{IV}}} \times 100\% F = AUC IV ​ AUC oral ​ ​ × 100%

Where AUC \text{AUC} AUC represents the Area Under the Plasma Concentration-Time Curve .

Intravenous (IV) Administration: Bypasses absorption barriers and first-pass hepatic extraction entirely, yielding F = 1.0 F = 1.0 F = 1.0 ( 100 % 100\% 100% ).

Oral (PO) Administration: Typically exhibits F < 1.0 F < 1.0 F < 1.0 due to incomplete gastrointestinal mucosal dissolution, gastric acid degradation, bacterial enzymatic metabolism, P-glycoprotein extrusion, and first-pass hepatic metabolism .

First-Pass Hepatic Elimination

Drugs absorbed through the gastrointestinal tract (stomach, small intestine, and proximal colon) enter the mesenteric venous drainage and travel via the hepatic portal vein directly to the liver before accessing systemic circulation. Extensive hepatic extraction or enzymatic biotransformation during this primary transit markedly reduces systemic bioavailability. For example, lidocaine undergoes approximately 70% to 90% first-pass hepatic metabolism, rendering oral administration clinically ineffective and necessitating parenteral or topical delivery.

  • Henderson-Hasselbalch Equation, Ion Trapping & Local Anesthetic Failure
  • The Physicochemical Basis of Ionization

The majority of therapeutic drugs are either weak acids or weak bases . Biological membranes consist of hydrophobic phospholipid bilayers that are permeable to uncharged, lipid-soluble molecules, but act as impermeable barriers to charged, water-soluble ionized species.

Weak Acids ( H A ⇌ H + + A − HA \rightleftharpoons H^+ + A^- H A ⇌ H + + A − ):

Non-ionized (protonated) form: H A HA H A (uncharged, lipophilic, membrane-permeable).

Ionized (unprotonated) form: A − A^- A − (negatively charged, hydrophilic, membrane-impermeable).

Weak Bases ( B H + ⇌ H + + B BH^+ \rightleftharpoons H^+ + B B H + ⇌ H + + B ):

Ionized (protonated) form: B H + BH^+ B H + (positively charged, hydrophilic, membrane-impermeable).

Non-ionized (unprotonated) form: B B B (uncharged, lipophilic, membrane-permeable).

The mathematical relationship governing the ratio of non-ionized to ionized species is defined by the Henderson-Hasselbalch equation :

pH − p K a = log ⁡ ( [ unprotonated ] [ protonated ] ) \text{pH} - \text{p}K_a = \log\left(\frac{[\text{unprotonated}]}{[\text{protonated}]}\right) pH − p K a ​ = lo g ( [ protonated ] [ unprotonated ] ​ )

For Weak Acids: pH − p K a = log ⁡ ( [ A − ] [ H A ] ) \text{For Weak Acids:} \quad \text{pH} - \text{p}K_a = \log\left(\frac{[A^-]}{[HA]}\right) For Weak Acids: pH − p K a ​ = lo g ( [ H A ] [ A − ] ​ )

For Weak Bases: pH − p K a = log ⁡ ( [ B ] [ B H + ] ) \text{For Weak Bases:} \quad \text{pH} - \text{p}K_a = \log\left(\frac{[B]}{[BH^+]}\right) For Weak Bases: pH − p K a ​ = lo g ( [ B H + ] [ B ] ​ )

Ion Trapping in Renal Tubular Clearance

When a drug crosses a biological membrane into a physiological compartment with a different pH, the fraction that ionizes cannot diffuse back across the lipid barrier, becoming "trapped" in that compartment.

Clinical Objective Target Intoxication Modulating Agent Biochemical Mechanism Clinical Board Pearl

Alkalinization of Urine Weak Acids (Aspirin / Salicylates, Phenobarbital, Methotrexate) Sodium Bicarbonate ( N a H C O 3 NaHCO_3 N a H C O 3 ​ ) Increases tubular urine pH ( > 7.5 > 7.5 > 7.5 ), shifting H A → H + + A − HA \rightarrow H^+ + A^- H A → H + + A − . The charged A − A^- A − cannot cross back across the tubular epithelium, accelerating renal excretion. Prevents systemic salicylic toxicity and pulmonary edema in aspirin overdose.

Acidification of Urine Weak Bases (Amphetamines, Phencyclidine / PCP) Ammonium Chloride ( N H 4 C l NH_4Cl N H 4 ​ Cl ) or Ascorbic Acid Decreases urine pH, shifting B + H + → B H + B + H^+ \rightarrow BH^+ B + H + → B H + . The charged B H + BH^+ B H + conjugate acid is trapped within the renal tubular lumen. Rarely used clinically due to risk of systemic metabolic acidosis; forced diuresis preferred.

High-Yield Board Pearl: Local Anesthetics in Acidic Infected Tissue

Local anesthetics (e.g., lidocaine, bupivacaine, mepivacaine) are chemically weak bases with dissociation constants ( p K a \text{p}K_a p K a ​ ) ranging between 7.8 7.8 7.8 and 9.0 9.0 9.0 :

B H + (Charged, active intracellular blocker) ⇌ B (Uncharged base, membrane-permeable) + H + (Proton) BH^+ \text{ (Charged, active intracellular blocker)} \rightleftharpoons B \text{ (Uncharged base, membrane-permeable)} + H^+ \text{ (Proton)} B H + (Charged, active intracellular blocker) ⇌ B (Uncharged base, membrane-permeable) + H + (Proton)

In healthy subcutaneous connective tissue with a physiological extracellular pH of 7.4 7.4 7.4 , a sufficient fraction of the anesthetic exists in the uncharged free base form ( B B B ) to penetrate the hydrophobic lipid epineurium and axonal membrane of sensory peripheral nerves. Once inside the axoplasm (physiological pH 7.2 7.2 7.2 ), the uncharged base B B B re-equilibrates into the charged protonated form B H + BH^+ B H + , which binds with high affinity to the intracellular channel pore of voltage-gated sodium channels ( N a V Na_V N a V ​ ) to halt depolarization and conduct nociceptive blockade.

Important

The Mechanism of Local Anesthetic Failure in Infected Tissue: When a podiatric physician attempts digital nerve blockade or infiltration around an acute purulent abscess, infected ulcer, or paronychia, the extracellular tissue pH drops precipitously to 5.5 − 6.0 5.5 - 6.0 5.5 − 6.0 as a consequence of bacterial anaerobic glycolysis, lactic acid accumulation, and inflammatory cellular lysis. According to the Henderson-Hasselbalch equation:

pH − p K a = log ⁡ ( [ B ] [ B H + ] ) ⟹ 5.5 − 7.9 = − 2.4 ⟹ [ B ] [ B H + ] = 10 − 2.4 ≈ 1 250 \text{pH} - \text{p}K_a = \log\left(\frac{[B]}{[BH^+]}\right) \implies 5.5 - 7.9 = -2.4 \implies \frac{[B]}{[BH^+]} = 10^{-2.4} \approx \frac{1}{250} pH − p K a ​ = lo g ( [ B H + ] [ B ] ​ ) ⟹ 5.5 − 7.9 = − 2.4 ⟹ [ B H + ] [ B ] ​ = 1 0 − 2.4 ≈ 250 1 ​

In this acidic microenvironment, the equilibrium is driven overwhelmingly toward the charged, water-soluble conjugate acid form ( B H + BH^+ B H + ). Less than 0.5 % 0.5\% 0.5% of the drug exists as the uncharged base ( B B B ). Because charged B H + BH^+ B H + cannot traverse the hydrophobic perineural lipid sheath, the local anesthetic is effectively locked out of the nerve axon. This produces severe anesthetic failure or incomplete sensory blockade , requiring regional nerve block proximal to the inflamed site (where tissue pH is normal) rather than direct local infiltration.

Loading diagram... Local Anesthetic Membrane Transport and Ion Trapping in Normal vs. Acidic Tissue

  • Volume of Distribution & Plasma Protein Binding
  • Apparent Volume of Distribution ( V d V_d V d ​ )

The Volume of Distribution ( V d V_d V d ​ ) is a theoretical pharmacokinetic parameter that equates the total amount of drug present in the entire body to the concentration of drug measured in the vascular plasma compartment:

V d = Total Amount of Drug in Body Plasma Drug Concentration ( C 0 ) = Dose (IV) C 0 V_d = \frac{\text{Total Amount of Drug in Body}}{\text{Plasma Drug Concentration } (C_0)} = \frac{\text{Dose (IV)}}{C_0} V d ​ = Plasma Drug Concentration ( C 0 ​ ) Total Amount of Drug in Body ​ = C 0 ​ Dose (IV) ​

V d V_d V d ​ does not reflect an actual physical anatomical volume; rather, it reflects the degree to which a drug partitions into peripheral tissues versus remaining confined within circulating plasma:

V d V_d V d ​ Compartment Size Numerical Range (70 kg adult) Physicochemical Drug Profile Exemplary Agents

Low V d V_d V d ​ (Vascular Plasma) 3 − 8 L 3 - 8\text{ L} 3 − 8 L ( 0.05 − 0.1 L/kg 0.05 - 0.1\text{ L/kg} 0.05 − 0.1 L/kg ) High molecular weight, highly ionized, or extensively bound to plasma albumin; unable to exit fenestrations. Warfarin ( V d ≈ 7 L V_d \approx 7\text{ L} V d ​ ≈ 7 L ), Heparin, Monoclonal antibodies

Medium V d V_d V d ​ (Extracellular Fluid) 12 − 16 L 12 - 16\text{ L} 12 − 16 L ( 0.2 − 0.3 L/kg 0.2 - 0.3\text{ L/kg} 0.2 − 0.3 L/kg ) Small, hydrophilic, water-soluble; distributes through capillary fenestrations into interstitial fluid, but cannot cross cell membranes. Aminoglycosides (Gentamicin), Vancomycin, Beta-lactams

High V d V_d V d ​ (Total Body Water & Tissue Storage) > 42 L > 42\text{ L} > 42 L up to > 1000 L > 1000\text{ L} > 1000 L ( > 0.6 L/kg > 0.6\text{ L/kg} > 0.6 L/kg ) Highly lipophilic, low plasma protein binding; distributes into intracellular fluid, accumulates in peripheral adipose or binds tissue proteins. Digoxin ( V d ≈ 500 L V_d \approx 500\text{ L} V d ​ ≈ 500 L ), Chloroquine, Morphine, Amiodarone

Plasma Protein Binding

Drugs in systemic circulation exist in a dynamic equilibrium between a protein-bound fraction and an unbound (free) fraction:

Albumin: Primary binding protein for acidic and neutral drugs (e.g., Warfarin, Phenytoin, Diazepam, NSAIDs, Ceftriaxone).

Alpha-1-Acid Glycoprotein (AAG): Acute-phase reactant synthesizing primarily in the liver; binds basic drugs (e.g., Lidocaine, Bupivacaine, Propranolol, Quinidine).

Note

Clinical Significance of Protein Binding: Only the unbound (free) drug fraction is pharmacologically active, capable of diffusing across vascular endothelium into target tissues, and subject to hepatic biotransformation and glomerular filtration. In clinical states characterized by severe hypoalbuminemia—such as hepatic cirrhosis, nephrotic syndrome, malnutrition, or chronic non-healing diabetic ulcerations with exudative protein loss—the free active fraction of highly protein-bound acidic drugs (e.g., phenytoin, warfarin) rises dramatically, producing unexpected clinical toxicity despite normal total plasma drug concentrations.

Biotransformation: Phase I vs. Phase II Metabolism

The ultimate goal of hepatic biotransformation is to convert lipophilic compounds into polar, water-soluble, hydrophilic metabolites that can be excreted by the kidneys or biliary tract.

Phase I Reactions: Functionalization

Phase I reactions introduce or unmask a polar functional group ( − O H , − N H 2 , − S H , − C O O H -OH, -NH_2, -SH, -COOH − O H , − N H 2 ​ , − S H , − COO H ) on the parent substrate. These reactions are catalyzed predominantly by the Cytochrome P450 (CYP450) monooxygenase enzyme superfamily localized within the smooth endoplasmic reticulum of hepatocytes.

Reaction Types: Oxidation (CYP-mediated), Reduction, and Hydrolysis.

Metabolic Outcome: Yields active, inactive, or toxic metabolites. In the case of prodrugs (e.g., codeine, clopidogrel, enalapril), Phase I bioactivation is required to generate the therapeutically active compound.

Geriatric Decline: Phase I metabolism declines significantly in elderly individuals due to decreased hepatic blood flow and hepatic microsomal mass, prolonging drug half-lives.

Cytochrome P450 Inducers vs. Inhibitors

Modulation of hepatic CYP450 isozymes (chiefly CYP3A4, CYP2C9, CYP2C19, CYP2D6, CYP1A2) accounts for major drug-drug interactions encountered on licensing examinations:

Category Pharmacokinetic Effect on Substrates Common Inducers / Inhibitors High-Yield Clinical Sequelae

CYP450 Inducers Accelerates substrate metabolism; ↓ \downarrow ↓ plasma drug levels → \rightarrow → therapeutic failure Rifampin , Phenytoin , Carbamazepine , St. John's wort , Phenobarbital, Chronic ethanol, Griseofulvin Co-administration of rifampin with warfarin decreases INR, risking recurrent DVT; reduces oral contraceptive efficacy.

CYP450 Inhibitors Decreases substrate metabolism; ↑ \uparrow ↑ plasma drug levels → \rightarrow → supratherapeutic toxicity Azole antifungals (Fluconazole, Ketoconazole, Itraconazole), Macrolides (Erythromycin, Clarithromycin; NOT Azithromycin), Ciprofloxacin , Cimetidine, Ritonavir, Grapefruit juice Co-administration of fluconazole with warfarin elevates INR, causing major gastrointestinal or operative bleeding; erythromycin co-administered with statins precipitates rhabdomyolysis.

Phase II Reactions: Conjugation

Phase II reactions conjugate the parent drug or Phase I intermediate with an endogenous hydrophilic substrate, creating large, highly polar, biologically inactive molecules ready for excretion.

Reaction Types:

Glucuronidation: Most common Phase II pathway; catalyzed by UDP-glucuronosyltransferases (UGT). Deficient in neonates (causing chloramphenicol "Gray Baby Syndrome").

Sulfation: Catalyzed by sulfotransferases.

Acetylation: Catalyzed by N-acetyltransferase (NAT2).

Glutathione Conjugation: Neutralizes toxic electrophilic intermediates, notably NAPQI generated by acetaminophen.

Geriatric Preservation: Phase II conjugation reactions (mnemonic: "Geriatrics have more GAS" — G lucuronidation, A cetylation, S ulfation) remain relatively preserved in elderly patients.

Pharmacogenetic Variation in Acetylation: Individuals are genetically categorized as fast acetylators or slow acetylators based on NAT2 polymorphisms. Slow acetylators possess reduced hepatic NAT2 activity, predisposing them to elevated drug concentrations and severe adverse reactions, including Drug-Induced Lupus Erythematosus (DILE) from Hydralazine, Procainamide, or Isoniazid (INH) , as well as INH-induced peripheral neuropathy.

  • Quantitative Pharmacokinetics: Dosing & Elimination Kinetics First-Order vs. Zero-Order Elimination
  • First-Order Elimination Zero-Order Elimination
  • [Plasma Conc vs. Time: Curve] [Plasma Conc vs. Time: Linear]
  • Concentration Concentration
  • │ * │ *
  • │ * │ *
  • │ * │ *
  • │ * │ *
  • │ * │ *
  • └───────────── Time └───────────── Time
  • Constant fraction (%)/time - Constant amount/time
  • Rate proportional to conc - Rate independent of conc (saturable)
  • Half-life is constant - Half-life decreases as conc falls
  • Most drugs at normal doses - Phenytoin, Ethanol, high-dose Aspirin
  • First-Order vs. Zero-Order Elimination Kinetics

Characteristic First-Order Elimination Zero-Order Elimination

Elimination Rate Constant fraction (percentage) of drug cleared per unit time (e.g., 10 % 10\% 10% per hour). Constant absolute amount of drug cleared per unit time (e.g., 10 mg 10\text{ mg} 10 mg per hour).

Concentration Dependence Rate of elimination is directly proportional to plasma concentration ( − d C d t = k ⋅ C -\frac{dC}{dt} = k \cdot C − d t d C ​ = k ⋅ C ). Rate of elimination is constant and independent of drug concentration ( − d C d t = k -\frac{dC}{dt} = k − d t d C ​ = k ).

Half-Life ( t 1 / 2 t_{1/2} t 1/2 ​ ) Constant , independent of dose or plasma concentration. Variable ; increases as dose or concentration increases.

Mechanism Elimination mechanisms (enzymes, transporters) operate well below saturation ( C ≪ K m C \ll K_m C ≪ K m ​ ). Elimination mechanisms are completely saturated ( C ≫ K m C \gg K_m C ≫ K m ​ ).

High-Yield Examples > 95 % > 95\% > 95% of all clinical drugs at therapeutic dosing. Phenytoin , Ethanol , Aspirin (at high/toxic doses) (Mnemonic: "PEA is a flat zero" ).

Core Pharmacokinetic Equations

Clearance (CL): C L = Rate of Elimination C p = 0.693 × V d t 1 / 2 \textbf{Clearance (CL):} \quad CL = \frac{\text{Rate of Elimination}}{C_p} = \frac{0.693 \times V_d}{t_{1/2}} Clearance (CL): C L = C p ​ Rate of Elimination ​ = t 1/2 ​ 0.693 × V d ​ ​

Half-Life ( t 1 / 2 ) : t 1 / 2 = 0.693 × V d C L \textbf{Half-Life } (t_{1/2}): \quad t_{1/2} = \frac{0.693 \times V_d}{CL} Half-Life ( t 1/2 ​ ) : t 1/2 ​ = C L 0.693 × V d ​ ​

Steady-State Concentration ( C s s ) : C s s = F × Dose CL × τ \textbf{Steady-State Concentration } (C_{ss}): \quad C_{ss} = \frac{F \times \text{Dose}}{\text{CL} \times \tau} Steady-State Concentration ( C ss ​ ) : C ss ​ = CL × τ F × Dose ​

Where τ \tau τ is the dosing interval.

Attainment of Steady State

When a drug is administered via continuous IV infusion or regular intermittent maintenance dosing, steady state ( C s s C_{ss} C ss ​ ) is reached when the rate of drug administration equals the rate of drug elimination. The time required to attain steady state depends exclusively on the drug's elimination half-life ( t 1 / 2 t_{1/2} t 1/2 ​ ) , completely independent of the dose, dosing interval, or route of administration:

  • 1 half-life = 50 % of C s s 1\text{ half-life} = 50\% \text{ of } C_{ss} 1 half-life = 50% of C ss ​
  • 2 half-lives = 75 % of C s s 2\text{ half-lives} = 75\% \text{ of } C_{ss} 2 half-lives = 75% of C ss ​
  • 3 half-lives = 87.5 % of C s s 3\text{ half-lives} = 87.5\% \text{ of } C_{ss} 3 half-lives = 87.5% of C ss ​

4 half-lives = 93.75 % of C s s 4\text{ half-lives} = 93.75\% \text{ of } C_{ss} 4 half-lives = 93.75% of C ss ​

4 − 5 half-lives = 95 − 97 % of C s s 4 - 5\text{ half-lives} = 95 - 97\% \text{ of } C_{ss} 4 − 5 half-lives = 95 − 97% of C ss ​ (Clinical Steady State attained)

Similarly, complete drug elimination (washout) following drug discontinuation requires 4 4 4 to 5 5 5 half-lives.

Loading Dose vs. Maintenance Dose Calculations

Loading Dose (LD): LD = C s s × V d F \textbf{Loading Dose (LD):} \quad \text{LD} = \frac{C_{ss} \times V_d}{F} Loading Dose (LD): LD = F C ss ​ × V d ​ ​

Maintenance Dose (MD): MD = C s s × C L × τ F \textbf{Maintenance Dose (MD):} \quad \text{MD} = \frac{C_{ss} \times CL \times \tau}{F} Maintenance Dose (MD): MD = F C ss ​ × C L × τ ​

Caution

Dose Adjustments in Renal Impairment: In patients with renal failure (decreased creatinine clearance), systemic clearance ( C L CL C L ) decreases while volume of distribution ( V d V_d V d ​ ) remains essentially unchanged. Therefore, the Loading Dose remains unaltered , ensuring rapid attainment of target plasma levels. However, the Maintenance Dose must be decreased (or the dosing interval τ \tau τ prolonged) in direct proportion to the reduction in renal clearance to avoid drug accumulation and severe toxicity.

  • Pharmacodynamics: Dose-Response Relationships & Antagonism
  • Graded Dose-Response Curves: Potency vs. Efficacy

Potency: Refers to the concentration or dose of a drug required to produce 50 % 50\% 50% of its maximal effect, represented by the E C 50 EC_{50} E C 50 ​ (effective concentration 50) . On a semi-logarithmic dose-response curve, a leftward shift indicates greater potency (less drug is needed to elicit the response).

Efficacy: Refers to the maximal biological response ( E max ⁡ E_{\max} E m a x ​ ) achievable by a drug at saturating concentrations. On a dose-response plot, efficacy is represented by the height (plateau) of the curve. Clinically, efficacy is vastly more important than potency.

Competitive vs. Non-Competitive Antagonists

Antagonist Type Receptor Interaction Effect on E C 50 EC_{50} E C 50 ​ (Potency) Effect on E max ⁡ E_{\max} E m a x ​ (Efficacy) Overcome by Increasing Agonist?

Competitive Antagonist Reversibly binds to the same active receptor site as the agonist; competes for occupancy. Increases E C 50 EC_{50} E C 50 ​ (Curve shifts RIGHT ) Unchanged ( E max ⁡ E_{\max} E m a x ​ preserved) YES ; high agonist concentrations displace the antagonist.

Non-Competitive Antagonist Irreversibly binds the active site (covalent bond) or binds an allosteric regulatory site. Unchanged E C 50 EC_{50} E C 50 ​ (or variable) Decreases E max ⁡ E_{\max} E m a x ​ (Curve shifts DOWNWARD ) NO ; agonist cannot overcome allosteric inactivation or covalent blockade.

Therapeutic Index & Therapeutic Drug Monitoring

The Therapeutic Index (TI) is a quantitative metric of drug safety, defined as the ratio between toxic dose and effective dose:

Therapeutic Index (TI) = T D 50 E D 50 ( or L D 50 E D 50 in preclinical animal models ) \text{Therapeutic Index (TI)} = \frac{TD_{50}}{ED_{50}} \quad \left(\text{or } \frac{LD_{50}}{ED_{50}} \text{ in preclinical animal models}\right) Therapeutic Index (TI) = E D 50 ​ T D 50 ​ ​ ( or E D 50 ​ L D 50 ​ ​ in preclinical animal models )

Wide Therapeutic Index: Large safety margin; plasma drug concentration monitoring is unnecessary (e.g., penicillin, beta-blockers).

Narrow Therapeutic Index (NTI): Small difference between therapeutic efficacy and lethal toxicity; requires therapeutic drug monitoring (TDM) of trough/peak levels to prevent catastrophe.

Classic Narrow TI Drugs: Warfarin , Digoxin , Lithium , Theophylline , Vancomycin , Aminoglycosides (Gentamicin/Tobramycin) , Phenytoin , and Carbamazepine .